DJIA 18,053.71 23.50 0.13%
NASDAQ 4,806.86 33.39 0.70%
S&P 500 2,088.77 6.89 0.33%
market minute promo


company name or ticker
Company Photos
(Click to zoom)

Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More

Noteworthy ETF Outflows: VTV, MRK, WMT, BMY

This Cancer Drug War Is Just Getting Started

The FDA approves Bristol-Myers Squibb's Opdivo, pitting it against Merck's Keytruda that was approved earlier this year.

The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)

Gilead Sciences Sovaldi was a superstar in 2014, helping Gilead to nearly a 40% year-to-date return. However, one hepatitis C drug developer has delivered 700% better returns to shareholders this year!

'Mad Money' Lightning Round: SunTrust Banks Is Terrific

Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst Blog

Medivation Licenses CureTech's Cancer Drug Pidilizumab - Analyst Blog

Who Is The Devil? Will Gilead Fall Or Soar In 2015?

3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015

Three Motley Fool analysts tell us which emerging biotechnology stocks they're watching in 2015.

FDA approves Bristol-Myer's skin cancer drug

See More Articles...